Picture a corridor lined with doors: blood cancers, solid tumors, autoimmune, genetic, and rare diseases, all opening wider at once. The field is no longer defined by a single “hero” modality cautiously opening one door at a time; it is becoming a platform era, where the same core technologies can unlock many rooms in the house of medicine simultaneously.
A decade ago, cell and gene therapies were framed as once‑in‑a‑generation moonshots for a handful of ultra‑rare conditions. Today, autologous CAR‑T, ex vivo gene therapies, and the first mesenchymal stromal cell (MSC) products have persuaded regulators, clinicians, and payers to treat them as part of mainstream practice rather than experimental rescue missions.
The question for 2026 is no longer if advanced therapies will matter, but where — and how fast.
CAR‑X in 2026: far beyond hematology
I imagine that ex vivo autologous CAR‑T still anchors the field, delivering deep, durable responses in B‑cell leukemias and lymphomas and an expanding body of experience in multiple myeloma. Yet its constraints are impossible to ignore: individualized manufacturing, vein‑to‑vein time, and cost continue to stretch clinical teams and limit who can be treated, where, and when. Attention in 2026 shifts to “CAR‑X” – a broader constellation of approaches that includes allogeneic CAR‑T, CAR‑NK, in vivo CAR platforms, and entirely new indications in autoimmune disease and solid tumors.
Early clinical signals in lupus, myasthenia gravis, and other refractory autoimmune conditions hint that resetting or eliminating autoreactive immune cells with CAR‑T could echo the transformative impact first seen in oncology. In parallel, multi‑specific CARs, logic‑gated designs, and armored constructs are being engineered to navigate dense solid‑tumor microenvironments with greater precision and fewer off‑tumor effects.
2026 will not close the book on CAR‑X, but it will begin to reveal which disease doors swing open easily — and which still need new engineering.
TIL therapies: solid tumors step onto the stage
Until very recently, cell therapy belonged almost entirely to blood cancers. That changed in 2024, when the FDA granted accelerated approval to lifileucel (Amtagvi), the first tumor‑infiltrating lymphocyte (TIL) therapy — and the first approved cell therapy for any solid tumor — for adults with unresectable or metastatic melanoma who had already progressed on checkpoint inhibitors and targeted therapy. This milestone has quickly moved TILs from “interesting experiment” to a serious pillar of the solid‑tumor playbook, with melanoma centers across the US and Europe standing up dedicated TIL programs and early data now emerging in gastrointestinal, lung, and other hard‑to‑treat cancers.
TIL therapy fits naturally into the platform‑era story: like autologous CAR‑T, it relies on ex vivo expansion of a patient’s own cells, but it starts with lymphocytes already trained by the tumor microenvironment, offering a highly personalized army of tumor‑reactive T cells. In 2026, the frontier is less about proving that TILs can work — they have now shown durable responses and guideline‑level status in advanced melanoma — and more about making them work reliably and accessibly: simplifying tumor procurement and logistics, standardizing manufacturing, and exploring engineered or cytokine‑free TIL products that can broaden use beyond elite centers and into additional solid‑tumor indications.
Autologous and allogeneic: complementary, not competitive
For years, the conversation has been framed as autologous versus allogeneic, as if the industry needed to pick a champion. In reality, 2026 is shaping up as the year these modalities are finally treated as complementary instruments in the same toolkit. Autologous therapies will likely retain the edge where patient‑specific biology is central, long‑term follow‑up is well mapped, and the infrastructure for individualized manufacturing is mature.
Allogeneic programs, by contrast, are positioned to dominate where scale and speed matter most. Off‑the‑shelf CAR‑T and CAR‑NK products promise on‑demand dosing from inventory, enabling treatment at centers that cannot support the full autologous workflow. However, autologous workflows become easier to take on with the advent of programs, such as the mobile leukapheresis centers that help decouple Apheresis (cell connection) from the clinical sites at scale across vast regions.
Challenges remain — immunogenicity, graft‑versus‑host risk, durability — but the trajectory points toward allogeneic platforms serving larger patient populations as those issues are addressed.
The strategic opportunity for 2026 is to design portfolios, clinical networks, and commercial models that let each modality shine where it is strongest, rather than forcing a single “true” answer into every indication.
Ex vivo gene therapy: precise, but intricate
Ex vivo gene therapies and gene‑edited cell products have proven to be a dependable route for correcting disease‑causing defects under tightly controlled conditions. Cells are collected from the patient or a donor, modified with viral vectors or genome‑editing tools, deeply characterized, and only then returned to the body. This choreography offers powerful control over editing outcomes, safety, and product quality.
That precision, however, comes with complexity. Supply chains are delicate, release testing is demanding, and every patient’s experience hinges on flawless coordination between collection, manufacturing, and clinical sites. In 2026, the focus shifts from “can we make it?” to “can we make it reliably, at scale?”
Industrialization is the watchword: decentralized apheresis and leukapheresis networks for starting material, modular cleanrooms, closed‑system processing, digital chain‑of‑identity, and harmonized assay platforms that can span entire pipelines.
Organizations that turn ex vivo production into repeatable, high‑fidelity manufacturing — rather than bespoke craftsmanship — will define the pace of progress.
In vivo gene therapy: toward scalable precision
In vivo gene therapy, delivering genetic instructions directly into the patient, has already rewritten the natural history of diseases like spinal muscular atrophy and certain hemophilias. These programs have validated the radical idea of a single‑dose, potentially durable intervention administered systemically or into a specific organ. As new vectors and non‑viral delivery systems mature, the map broadens to ophthalmology, neurology, metabolic disease, and beyond.
The 2026 frontier has two defining edges.
- First, regulators in the US and Europe are embracing “platform” thinking — allowing sponsors to leverage established vector and manufacturing data when they move to new genes or mutations, rather than starting from scratch each time.
- Second, the community is investing heavily in long‑term safety, immunogenicity, and durability monitoring, building real‑world evidence, registries, and life‑long follow‑up into the blueprint of each program.
In vivo therapies may ultimately become the default route for reaching large, geographically dispersed patient populations — but only if safety and reliability are treated as core engineering requirements, not late‑stage hurdles.
MSC‑based therapies: from quiet promise to visible practice
Mesenchymal stromal/stem cell therapies have often been overshadowed by CAR‑T and gene editing, quietly advancing while other modalities took the spotlight. Yet they have crossed important thresholds: multiple MSC products are now approved for graft‑versus‑host disease and a range of inflammatory and orthopedic indications, underscoring their versatility in immunomodulation, trophic support, and tissue repair.
In the coming year, MSCs and MSC‑derived extracellular vesicles are likely to move closer to center stage as “adjacent” tools — enhancing outcomes where inflammation, fibrosis, or microenvironment damage limits the benefit of other treatments.
Regulators are simultaneously tightening expectations around potency assays, product consistency, and clinical evidence, drawing a sharp line between rigorously developed MSC therapeutics and unregulated “stem cell” interventions.
Teams that can clear those higher bars will find MSCs a powerful complement to CAR‑X and gene therapy strategies, not a competing narrative.
Policy and infrastructure: the invisible accelerators
Science sets direction; policy and infrastructure dictate speed. Across the US, Europe, and Asia, regulators are reshaping the rules of the road for cell and gene therapies.
- In the United States, the FDA is rolling out new CGT‑specific guidance on innovative trial designs, long‑term follow‑up, and chemistry‑manufacturing‑controls tailored to complex biologics.
- In Europe, the EMA continues to refine its advanced therapy medicinal product (ATMP) framework, working to align pivotal trial expectations with the US while preserving regional nuances.
- Asia is no longer a “later” market — it is an active engine in its own right. Authorities in Japan, South Korea, China, and other APAC countries are introducing accelerated pathways, conditional approvals, and clearer CGT roadmaps, even as differences in data standards and post‑marketing requirements create a patchwork to navigate.
Across these regions, payers and health systems are experimenting with outcomes‑based agreements, annuity‑style payments, and regional treatment networks that can accommodate high‑complexity products without overwhelming budgets. The through‑line is clear: advanced therapies are welcome, but only with credible long‑term safety plans, robust manufacturing, and evidence packages that hold up in real‑world use. For developers and partners, 2026 is the year to design regulatory, pricing, and evidence strategies into programs from the first protocol, not bolt them on at the end.
Moving a Mission Forward
This is where the nonprofit organization I have the privilege to lead, BBG Advanced Therapies, comes into the picture. BBG brings a specific kind of capability to this platform era: end‑to‑end, cell‑centric infrastructure that serves the industry and sits at the intersection of collection, manufacturing, and testing. Our portfolio spans donor and patient cell collection (including a mobile leukapheresis center), process development, cGMP manufacturing, cryopreservation, and advanced assays designed to align with FDA, EMA, and PMDA expectations.
Rather than anchoring everything to a single product class, BBG Advanced Therapies is intentionally built to flex. The same backbone supports autologous and allogeneic programs, MSC‑based projects, and a mix of ex vivo and in vivo‑adjacent workflows through flexible cleanrooms, process‑development labs, and a transatlantic CDMO network with CELLforCURE by Seqens.
In that sense, BBG serves less as a “provider” and more as a working example of the integrated architecture this field now requires: connected starting‑material collection, regional manufacturing capacity, and fit‑for‑purpose testing that together make it more straightforward to move advanced therapies from concept into real‑world use at scale.
Stepping into 2026
As you stand in your own corridor of possibilities, consider which door your organization is best placed to open in the year ahead. Perhaps it is deepening your footprint in hematologic malignancies with next‑generation CAR‑X, pivoting into autoimmune disease, or building the infrastructure required for in vivo gene therapy and MSC‑based regenerative programs. The field is moving quickly, but there is still room for deliberate, well‑architected choices.
My commitment to you is that Blueprint for Breakthroughs will continue to follow this journey — spotlighting real‑world experiences, regulatory shifts, and design decisions that separate ambitious slide decks from executable plans. The more aligned the ecosystem becomes, the more doors we can open together for patients in 2026 and beyond.
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies
